This effect may be in line with recent data suggesting that low-grade CRP elevation may protect against negative health outcomes, including schizophrenia and prostate cancer (Prins et al., 2016; Reay et al.; Said et al., 2022). The gene discussed is CRP; the disease is prostate carcinoma.